Targeting DDR1 Kinase to Address Tumor Dissemination, Immune Exclusion, and Therapeutic Resistance
Generation of profound anti-tumor immunity by AUR109, a spectrum-selective kinase inhibitor, either as a single agent or in combination with immune checkpoint inhibitors
AACR Annual Meeting, April 2023
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.
Mol Cancer Ther. 2019 18(1):28-38